石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group's Gadobutrol has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Gadobutrol is a magnetic resonance imaging contrast agent used for adults and children of all ages (including full-term newborns), and is mainly used for contrast-enhanced magnetic resonance imaging (CE-MRI) examinations of lesions in various parts of the body (including the brain and spinal cord), as well as contrast-enhanced magnetic resonance angiography (CE-MRA) examinations of various parts of the body.

Gadobutrol, as a new generation of magnetic resonance imaging contrast agent with macrocyclic structure, is more stable and safer than Gadopentetate Dimeglumine with linear structure, offering advantage for clinical substitution. Gadolinium is a rare-earth metal, and the Group is actively developing an integrated business of bulk drugs and injection preparations under Gadolinium category.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 21 July 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.